aims to evaluate new generation antidepressants in relation to the placebo responsemethods i review metaanalyses in which response to antidepressant medication and response to placebo were calculatedresults all but one of these metaanalyses included unpublished as well as published trialsmost trials failed to show a significant advantage of ssris over inert placebo and the differences between drug and placebo are not clinically significant for most depressed patientsdocuments obtained from the us food and drug administration fda revealed an explicit decision to keep this information from the public and from prescribing physiciansconclusions because they do not incur drug risks exercise and psychotherapy which show at benefits at least equal to those of antidepressants may be a better treatment choice for depressed individuals